FindTrial
Sign In

A retrospective study of the safety and efficacy of ALPPS versus PVE two-step hepatectomy in the treatment of liver cancer

A retrospective study of the safety and efficacy of ALPPS versus PVE two-step hepatectomy in the treatment of liver cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300076438
Enrollment
Unknown
Registered
2023-10-09
Start date
2023-10-09
Completion date
Unknown
Last updated
2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary hepatic carcinoma

Interventions

ALPPS group:None
PVE group:None

Sponsors

The First Affiliated Hospital of PLA Army Military Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: (1) Patients diagnosed with primary liver cancer and treated for the first time (2) Insufficient liver volume remaining after direct surgical resection of the tumor (FLR < 40% in cirrhosis and < 30% in non-cirrhosis) (3) The main surgical methods were ALPPS or PVE two-step hepatectomy (4) Complete clinical data

Exclusion criteria

Exclusion criteria: (1) Patients with intrahepatic cholangiocarcinoma (ICC), metastatic liver cancer, etc (2) History of liver cancer treatment before surgery (3) Extensive tumor metastasis (4) The interval between the first and second operations was more than 6 months

Design outcomes

Secondary

MeasureTime frame
The incidence of complications within 30 days after operation in ALPPS group and PVE group was analyzed;—

Primary

MeasureTime frame
The 1-year and 3-year overall survival rates were measured in the ALPPS and PVE groups;—

Countries

China

Contacts

Public ContactLeida Zhang

The First Affiliated Hospital of PLA Army Medical University

2518569931@qq.com+86 135 0832 0249

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026